Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy  

作　　者：Liang Wang Yong-Zhi Diao Xin-Fu Ma Yu-Shuang Luo Qi-Jing Guo Xiao-Qian Chen 

机构地区：[1]Department of Gastrointestinal Oncology Surgery,Affiliated Hospital of Qinghai University,Xining 810000,Qinghai Province,China [2]Department of Gastroenterology,The First People’s Hospital of Xining,Xining 810000,Qinghai Province,China [3]Department of Medical Oncology,Affiliated Hospital of Qinghai University,Xining 810000,Qinghai Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2024年第10期3277-3287,共11页世界胃肠外科杂志（英文）

基　　金：Supported by the 2021 Key Topic of the Qinghai Provincial Health System-Guiding Plan Topic,No.2021-WJZDX-43.

摘　　要：BACKGROUND At present,immune checkpoint inhibitors(ICIs)remain the 1st-line therapy me-thod for patients suffering from high microsatellite instability/deficient misma-tch repair metastatic colorectal cancer(mCRC).However,ICI treatments demon-strate minimal therapeutic efficacy against microsatellite stable(MSS)/proficient mismatch repair(pMMR)CRC.This is mainly because this type of tumor is a“cold tumor”with almost no lymphocyte infiltration.Anti-angiogenic drugs have been found to improve the immune microenvironment by promoting many immune cells to enter the immune microenvironment,thereby exerting anti-tumor effects.AIM To investigate the effects of ICIs combined with bevacizumab monoclonal anti-body on tumor immune cells in MSS/pMMR advanced CRC patients with first-line treatment failure.METHODS A total of 110 MSS/pMMR patients with advanced CRC after first-line treatment failure in the Affiliated Hospital of Qinghai University were enrolled for a ran-domized controlled trial.In short,patients in the experimental group(n=60)were given sintilimab plus bevacizumab for 4 cycles,and those in the control group(n=50)patients were treated with FOLFIRI combined with bevacizumab for 4 cycles.The expression levels of cluster of differentiation(CD)8(+)T cells,tumor-associated macrophages(TAMs),and cancer-associated fibroblasts(CAFs)were comprehensively evaluated to assess the effects of sintilimab combined with bevacizumab on MSS/pMMR advanced CRC sufferers following failure of 1st-line therapy.RESULTS The positive expression rates of CD8(+)T lymphocytes(30%vs 50%),TAMs(23.30%vs 60%),and CAFs(23.30%vs 50%)before and after treatment in both groups exhibited statistical significance(P<0.05).Additionally,the therapeutic effects of both groups(partial remission:26.67%vs 10%;objective response rate:26.70%vs 10%)were significantly different(P<0.05).Although the experimental group showed a higher progression-free survival,median progression-free survival,and disease control rate than the control group,the difference was n

关 键 词：Immune checkpoint inhibitors BEVACIZUMAB Colorectal cancer Cytotoxic T lymphocytes Tumor-associated macrophages Cancer-associated fibroblasts 

分 类 号：R735.34[医药卫生—肿瘤]